Table 3 Evidence supporting CRRM for women with BRCA mutations
First author | Year | Total patients in cohort study | BRCA1 patients | BRCA2 patients | Total number of patients with BRRM | BRCA1 in BRRM | BRCA2 in BRRM | Median follow-up (year) | Development of BC (%) | RR (95% CI) | HR of all-cause mortality (95% CI) | HR of BC-specific mortality (95%CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TC Van Sprundel | 2005 | 148 | 115 | 33 | 79 | 60 | 19 | 7.4 | 1.30% | 0.04 (0.01-0.31) | 0.35 (0.09-1.39) | 3.80% |
Evans | 2013 | 718 | 357 | 361 | 105 | - | - | 7.2 | 4.90% | 0.12 (0.02-0.88) | 0.48 (0.19-1.14) | - |
Metcalfe | 2014 | 390 | 226 | 158 | 181 | 103 | 76 | 13 | - | 0.02 (0.00-0.18) | 0.58 (0.34-0.97) | 0.52 (0.29-0.93); 9.9% |
Heemkerk-Gerritsen | 2014 | 583 | 454 | 129 | 242 | 193 | 49 | 5.2 | 2% | 0.14 (0.05-0.35) | 0.49 (0.29-0.82) | - |
Soenderstrup | 2018 | 235 | 141 | 96 | 235 | 141 | 96 | 9.01 | - | - | 0.42 (0.21-0.84) | - |